Clearside Biomedical Inc
NASDAQ:CLSD
Intrinsic Value
Clearside Biomedical, Inc. is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. [ Read More ]
The intrinsic value of one CLSD stock under the Base Case scenario is 0.74 USD. Compared to the current market price of 1.31 USD, Clearside Biomedical Inc is Overvalued by 44%.
Valuation Backtest
Clearside Biomedical Inc
Run backtest to discover the historical profit from buying and selling CLSD stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Clearside Biomedical Inc
Current Assets | 30.1m |
Cash & Short-Term Investments | 28.9m |
Receivables | 170k |
Other Current Assets | 1m |
Non-Current Assets | 3.9m |
PP&E | 3.9m |
Other Non-Current Assets | 30k |
Current Liabilities | 6.8m |
Accounts Payable | 2.2m |
Accrued Liabilities | 4.5m |
Other Current Liabilities | 75k |
Non-Current Liabilities | 43.1m |
Other Non-Current Liabilities | 43.1m |
Earnings Waterfall
Clearside Biomedical Inc
Revenue
|
8.2m
USD
|
Cost of Revenue
|
-355k
USD
|
Gross Profit
|
7.9m
USD
|
Operating Expenses
|
-32.7m
USD
|
Operating Income
|
-24.8m
USD
|
Other Expenses
|
-7.6m
USD
|
Net Income
|
-32.5m
USD
|
Free Cash Flow Analysis
Clearside Biomedical Inc
What is Free Cash Flow?
CLSD Profitability Score
Profitability Due Diligence
Clearside Biomedical Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Clearside Biomedical Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
CLSD Solvency Score
Solvency Due Diligence
Clearside Biomedical Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Clearside Biomedical Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CLSD Price Targets Summary
Clearside Biomedical Inc
According to Wall Street analysts, the average 1-year price target for CLSD is 5.61 USD with a low forecast of 4.04 USD and a high forecast of 8.4 USD.
Ownership
CLSD Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CLSD Price
Clearside Biomedical Inc
Average Annual Return | 13.25% |
Standard Deviation of Annual Returns | 58.24% |
Max Drawdown | -91% |
Market Capitalization | 97.9m USD |
Shares Outstanding | 74 720 000 |
Percentage of Shares Shorted | 0.32% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Clearside Biomedical, Inc. is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. The company is headquartered in Alpharetta, Georgia and currently employs 34 full-time employees. The company went IPO on 2016-06-02. The firm is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. The company is focused on developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector, and it also partners with companies developing other ophthalmic therapeutics to be administered using its SCS injection platform. Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. Its pipeline includes CLS-AX, CLS-301 and Gene Therapy.
Contact
IPO
Employees
Officers
The intrinsic value of one CLSD stock under the Base Case scenario is 0.74 USD.
Compared to the current market price of 1.31 USD, Clearside Biomedical Inc is Overvalued by 44%.